Danielle M. Brander
Expertise in
12
conditions

Dr. Danielle M. Brander

Hematology Oncology | Hematology | Oncology
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
15 Years of Experience
Expertise in
12
conditions
Duke Health Integrated Practice Inc
2351 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Danielle Brander is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Brander has been practicing medicine for over 15 years is highly rated in 12 conditions, according to our data. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration. Dr. Brander is currently accepting new patients.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: August 19, 2024
Intervention Type: Drug
Study Phase: Early Phase 1
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug, Combination product
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
Enrollment Status: Completed
Publish Date: August 08, 2023
Intervention Type: Biological, Drug, Other
Study Drugs: Entospletinib, Obinutuzumab
Study Phase: Phase 1/Phase 2
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

73 Total Publications

Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy.
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy.
Journal: Transplantation and cellular therapy
Published: May 30, 2025
Similar Doctors
Diane Reidy
Expertise in
18
conditions
Dr. Diane Reidy
Hematology Oncology | Hematology | Oncology
Expertise in
18
conditions
Dr. Diane Reidy
Hematology Oncology | Hematology | Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.3 miles away)
919-681-6900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Diane Reidy is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Reidy is highly rated in 18 conditions, according to our data. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, Pancreaticoduodenectomy, and Liver Embolization.

Expertise in
17
conditions
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
 (0.3 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Ashley is highly rated in 17 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Expertise in
12
conditions
Dr. Joshua F. Zeidner
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Joshua F. Zeidner
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.6 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Zeidner is highly rated in 12 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Zeidner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brander's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile